Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK

Holly Cranmer, Tanja Podkonjak, Eugene Benson, Jonathon Dabora, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142338

Published: 2020

Journal Articles

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Amy Barber, PhD, John R Jones, MD, Harvey Che, Yann-Vai Le Bihan, Niels Weinhold, PhD, Cody Ashby, PhD, Brian A Walker, PhD, Christopher P. Wardell, PhD MSc, BSc, Hannah Wang, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Faith E. Davies, Rajesh Chopra, MD, Gareth Morgan, MD PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140024

Published: 2020

Journal Articles

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Tom Menzies, Faith E. Davies, Ritika Rana, Jennifer Pinney, Gordon Cook, MD, Walter Martin Gregory, PhD, Matthew W Jenner, John R Jones, MD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Gareth Morgan, MD PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, David Cairns, MSc, PhD, Mark T Drayson, MB ChB, PhD FRCPath

Blood (2020) 136 (Supplement 1): 40–43.

https://doi.org/10.1182/blood-2020-139238

Published: 2020

Journal Articles

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Jessica Caro, MD, David Cairns, MSc, PhD, Tom Menzies, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Eileen M Boyle, MD MSc, Gareth Morgan, MD PhD, Gordon Cook, MB ChB, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Walter M Gregory, PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Brian Walker, PhD, Jennifer LJ Heaney, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Faith E. Davies

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-133516

Published: 2020

Journal Articles

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Ruth Mary de Tute, PhD FRCPath, Andy C Rawstron, BSc, PhD, David A Cairns, MSc, PhD, Charlotte Pawlyn, MB BChir, Faith E Davies, MD, Corinne Collett, Martin F Kaiser, John R Jones, MD, Anna Waterhouse, Alina Striha, MSc, Gordon Cook, MDPhD, Matthew W Jenner, MD, Nigel H Russell, MD, Mark T Drayson, MD PhD, Walter M Gregory, PhD, Graham H Jackson, MD PhD, Gareth J Morgan, MD PhD, Roger G Owen, MD

Blood (2016) 128 (22): 245.

https://doi.org/10.1182/blood.V128.22.245.245

Published: 2016

Journal Articles

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1143.

https://doi.org/10.1182/blood.V128.22.1143.1143

Published: 2016

Journal Articles

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1144.

https://doi.org/10.1182/blood.V128.22.1144.1144

Published: 2016

Journal Articles

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Blood (2016) 128 (22): 3271.

https://doi.org/10.1182/blood.V128.22.3271.3271

Published: 2016

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Charlotte Pawlyn, MB BChir, Michael Bright, PhD, Amy Buros, PhD, Caleb K. Stein, MS, Zoe Walters, PhD, Lauren Aronson, PhD, Fabio Mirabella, PhD, Martin F Kaiser, MD, John R Jones, MD, Brian A Walker, PhD, Graham H Jackson, MD PhD, Paul Clarke, PhD, Leif Bergsagel, MD, Paul Workman, PhD, Marta Chesi, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3289.

https://doi.org/10.1182/blood.V128.22.3289.3289

Published: 2016

Journal Articles

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 244.

https://doi.org/10.1182/blood.V128.22.244.244

Published: 2016

Journal Articles

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Blood (2016) 128 (22): 804.

https://doi.org/10.1182/blood.V128.22.804.804

Published: 2016

Journal Articles

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Sarah E Fordham, PhD, Helen J Blair, PhD, Claire J Elstob, PhD, Deepali Pal, PhD, Nicola Curtin, PhD, Paul Milne, PhD, Matthew Collin, MD PhD, Graham H Jackson, MD MBBS, Helen J Marr, MD PhD, Olaf Heidenreich, PhD, Ruth Plummer, John Pollard, PhD, Tobias F. Menne, MD PhD FRCPath, Gail L Jones, MD BMBS, James M Allan, DPhil

Blood (2016) 128 (22): 4031.

https://doi.org/10.1182/blood.V128.22.4031.4031

Published: 2016

Journal Articles

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Blood (2016) 128 (22): 4412.

https://doi.org/10.1182/blood.V128.22.4412.4412

Published: 2016

Journal Articles

The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma

Brian A Walker, PhD, Mehmet K. Samur, PhD, Konstantinos Mavrommatis, Cody Ashby, PhD, Christopher P Wardell, PhD, Maria Ortiz, PhD, Fadi Towfic, Caleb K. Stein, MS, Michael A Bauer, PhD, Michael Amatangelo, PhD, Giovanni Parmigiani, PhD, Zhinuan Yu, PhD, Matthew Trotter, Herve Avet-Loiseau, MD PhD, Graham H Jackson, MD PhD, Kenneth C. Anderson, Anjan Thakurta, PhD, Nikhil C. Munshi, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 196.

https://doi.org/10.1182/blood.V128.22.196.196

Published: 2016

Journal Articles

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Blood (2016) 128 (22): 4407.

https://doi.org/10.1182/blood.V128.22.4407.4407

Published: 2016

Journal Articles

Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases

Martin F Kaiser, MD, Eileen Mary Boyle, MD PhD, Brian A Walker, PhD, Dil B Begum, Paula Proszek, David C Johnson, PhD, Charlotte Pawlyn, MB BChir, John R Jones, MD, Suvi Savola, PhD, Roger G Owen, Mark T Drayson, MD PhD, David A Cairns, Gordon Cook, MD PhD, Walter M Gregory, Richard S Houlston, MDPhDFRCP, Faith E Davies, MD, Graham H Jackson, MD, Gareth J Morgan, MD PhD

Blood (2015) 126 (23): 2981.

https://doi.org/10.1182/blood.V126.23.2981.2981

Published: 2015

Journal Articles

Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients

Blood (2015) 126 (23): 2983.

https://doi.org/10.1182/blood.V126.23.2983.2983

Published: 2015

Journal Articles

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Caleb K. Stein, MS, Faith E Davies, MD, Christoph Heuck, MD, Niels Weinhold, PhD, Shweta S. Chavan, PhD, Brian A Walker, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Martin F Kaiser, MD, Graham H Jackson, MD PhD, Pieter Sonneveld, MD PhD, Hartmut Goldschmidt, MD, Peter Leif Bergsagel, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 4173.

https://doi.org/10.1182/blood.V126.23.4173.4173

Published: 2015

Journal Articles

Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases

John R Jones, MD, David A Cairns, Rachel Sigsworth, Corinne Collett, Charlotte Pawlyn, MB BChir, Alina Striha, Lorenzo Melchor, PhD, Martin F Kaiser, MD, Mark T Drayson, MD PhD, Faith E Davies, MD, Walter M Gregory, Kevin Boyd, MD, Roger G Owen, Graham H Jackson, MD, Gareth J Morgan, MD PhD

Blood (2015) 126 (23): 1847.

https://doi.org/10.1182/blood.V126.23.1847.1847

Published: 2015

Journal Articles

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Blood (2015) 126 (23): 371.

https://doi.org/10.1182/blood.V126.23.371.371

Published: 2015

NARROW

Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases

Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only